| Mr Bernard J Gilligan, CRNA | |
|
100 N Academy Ave, Danville, PA 17822-2025 | |
| (570) 271-6621 | |
| Not Available |
| Full Name | Mr Bernard J Gilligan |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 19 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003884479 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN330958L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regional Hospital Of Scranton | Scranton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital Anesthesia Solutions Of Philadelphia Llc | 5597197046 | 25 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
A study in mice reveals an elegant circuit within the developing visual system that helps dictate how the eyes connect to the brain. The research, funded by the National Institutes of Health, has implications for treating amblyopia, a vision disorder that occurs when the brain ignores one eye in favor of the other.
Jennifer Sieck knew something had to be done when she would lie in bed most of the day and night.
Adults are widely exposed to e-cigarette marketing through the media, but those messages reach different demographic groups in different ways, according to a survey by researchers at the University of Illinois at Chicago's Institute for Health Research and Policy.
› Verified 1 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
A study in mice reveals an elegant circuit within the developing visual system that helps dictate how the eyes connect to the brain. The research, funded by the National Institutes of Health, has implications for treating amblyopia, a vision disorder that occurs when the brain ignores one eye in favor of the other.
Jennifer Sieck knew something had to be done when she would lie in bed most of the day and night.
Adults are widely exposed to e-cigarette marketing through the media, but those messages reach different demographic groups in different ways, according to a survey by researchers at the University of Illinois at Chicago's Institute for Health Research and Policy.
› Verified 1 days ago
| Entity Name | Capital Anesthesia Solutions Of Philadelphia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407402365 PECOS PAC ID: 5597197046 Enrollment ID: O20191121001321 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
A study in mice reveals an elegant circuit within the developing visual system that helps dictate how the eyes connect to the brain. The research, funded by the National Institutes of Health, has implications for treating amblyopia, a vision disorder that occurs when the brain ignores one eye in favor of the other.
Jennifer Sieck knew something had to be done when she would lie in bed most of the day and night.
Adults are widely exposed to e-cigarette marketing through the media, but those messages reach different demographic groups in different ways, according to a survey by researchers at the University of Illinois at Chicago's Institute for Health Research and Policy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Bernard J Gilligan, CRNA 100 N Academy Ave, Danville, PA 17822-3034 Ph: (570) 271-6144 | Mr Bernard J Gilligan, CRNA 100 N Academy Ave, Danville, PA 17822-2025 Ph: (570) 271-6621 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
A study in mice reveals an elegant circuit within the developing visual system that helps dictate how the eyes connect to the brain. The research, funded by the National Institutes of Health, has implications for treating amblyopia, a vision disorder that occurs when the brain ignores one eye in favor of the other.
Jennifer Sieck knew something had to be done when she would lie in bed most of the day and night.
Adults are widely exposed to e-cigarette marketing through the media, but those messages reach different demographic groups in different ways, according to a survey by researchers at the University of Illinois at Chicago's Institute for Health Research and Policy.
› Verified 1 days ago
Mr. Thomas G. Smith, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6621 | |
Matthew Payne, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Ms. Marianne E. Pavis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6621 | |
Ms. Mary M. Podgurski, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6621 | |
Mr. Daniel C. Pace, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6621 Fax: 570-271-6762 | |
Stacey Vernon, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 N Aademy Ave, Danville, PA 17822 Phone: 570-271-6621 Fax: 570-271-6762 |